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Coffee’s long-term effect on cognitive function remains unclear with studies suggesting both benefits 
and adverse effects. We used Mendelian randomization to investigate the causal relationship between 
habitual coffee consumption and cognitive function in mid- to later life. This included up to 415,530 
participants and 300,760 coffee drinkers from 10 meta-analysed European ancestry cohorts. In each 
cohort, composite cognitive scores that capture global cognition and memory were computed using 
available tests. A genetic score derived using CYP1A1/2 (rs2472297) and AHR (rs6968865) was chosen 
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as a proxy for habitual coffee consumption. Null associations were observed when examining the 
associations of the genetic score with global and memory cognition (β = −0.0007, 95% C.I. −0.009 to 
0.008, P = 0.87; β = −0.001, 95% C.I. −0.005 to 0.002, P = 0.51, respectively), with high consistency 
between studies (Pheterogeneity > 0.4 for both). Domain specific analyses using available cognitive 
measures in the UK Biobank also did not support effects by habitual coffee intake for reaction time, 
pairs matching, reasoning or prospective memory (P ≥ 0.05 for all). Despite the power to detect very 
small effects, our meta-analysis provided no evidence for causal long-term effects of habitual coffee 
consumption on global cognition or memory.
Coffee is one of the most widely consumed beverages worldwide1. Its health benefits and risks have long been 
debated, with some studies suggesting reductions in the risk of various diseases2–5 and mortality6–8, while other 
studies have suggested a potential increase in cardiovascular risk9.
Comprised of over 1,000 chemical compounds, coffee gains its popularity through its acute stimulatory effects, 
which are attributed to the pharmacological activity of caffeine1. Caffeine can readily cross the blood-brain bar-
rier, and is believed to exert its neurocognitive effects by antagonizing adenosine receptors in the central nervous 
system1. Large-scale meta-analyses of prospective studies suggested that higher coffee consumption is associated 
with a lower risk for Alzheimer’s disease10,11, while a recent genetic study using summary data from large con-
sortia did not support a causal association12. Studies on the effects of coffee consumption on specific cognitive 
domains have yielded mixed results for executive function and memory, with some suggesting benefits, and 
others showing null or adverse effects13–15. Inconsistent findings may reflect methodological problems commonly 
seen with dietary exposures including confounding and reverse causation, the latter being particularly important 
in this case given that caffeine intake is typically one of the first behaviors to be altered when the individual’s 
health status declines16.
Randomised clinical trials are the gold standard for testing causal effects, however, these are expensive to 
undertake and it is difficult to examine influences of prolonged exposures. An alternative is Mendelian random-
ization, also called “nature’s randomised trial”, which is a non-invasive and cost-effective observational approach 
to identify possible causal associations17. In Mendelian randomization, causality is inferred from the association 
between exposure-related genetic variants and the outcome of interest18,19. As genotypes are assigned (at random) 
at conception they will not be generally affected by disease or social and lifestyle factors, allowing us to over-
come some of the common problems with observational epidemiology. For a commonly used addictive stimulant 
such as caffeine, which has been proposed to have both adverse and beneficial effects on cognitive outcomes14,20, 
Mendelian randomization is therefore an attractive approach to use as it allows us to address issues both in rela-
tion to safety and preventative potential.
Genome-wide association studies to date have identified 8 loci influencing habitual coffee intakes21,22. Two 
common genetic variants have the strongest effects and known biological mechanisms, one located between 
the cytochrome P450 1A1 (CYP1A1) and CYP1A2 gene regions (rs2472297) and the other 51 kb upstream the 
aryl-hydrocarbon receptor (AHR) gene (rs6968865)23. CYP1A2 accounts for ~95% of hepatic caffeine clearance, 
and AHR plays a key role in metabolizing xenobiotics and inducing the transcription of CYP1A224. In this study, 
including individual level data for up to 415,530 European ancestry participants, we examined the causal associ-
ation between genetically instrumented habitual coffee intake, and cognitive function in mid- to later-life, with 
the aim of establishing causal evidence for potential long-term cognitive effects of coffee consumption. Given 
the variants influencing patterns of coffee consumption also affect caffeine intake and clearance23–25, secondary 
analyses were conducted with respect to habitual tea and caffeine intakes.
Methods
Study population. Data came from 10 European cohorts including the 1958 British birth cohort (1958BC), 
UK Biobank, Mothers of Avon Longitudinal Study of Parents and Children (ALSPAC-M), Northern Finland 
Birth Cohorts 1966 (NFBC1966), Cardiovascular Risk in Young Finns Study (YFS), Helsinki Birth Cohort Study 
(HBCS), Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS), Uppsala Longitudinal Study 
of Adult Men (ULSAM), Swedish twin registry (STR) and TwinGene studies. Participants in each study have pro-
vided an informed consent, and each study is covered by ethical approvals from the relevant ethics committees. 
A more detailed description of each cohort is provided in the supplementary text. Data analysis in each cohort 
was restricted to participants with complete information on AHR and CYP1A1/2 genetic variants, who also had 
information on habitual coffee intake and cognitive measures.
Genetic variants. Genome-wide association studies to date have identified eight loci influencing habitual 
coffee intake patterns21,22. For our primary analyses we chose the two strongest loci that have well-characterized 
biological functions affecting caffeine metabolism, CYP1A1/2 and AHR24. The remaining six loci (POR, EFCAB5, 
GCKR, ABCG2, MLXIPL, and BDNF) were used in secondary analyses. Our strategy for the selection of instru-
mental variables is expanded upon in Supplementary Fig. S1.
The primary variant for CYP1A1/2 was rs2472297, and for AHR rs6968865. In cohorts where rs6968865 was 
unavailable, its proxy, rs6968554 (r2 = 1.0) or rs4410790 (r2 = 0.97) was used (Supplementary Table S1). As the two 
variants had very similar effects on habitual coffee intake in the original GWAS21 we used an unweighted genetic 
score constructed by summing the number of intake-increase alleles in CYP1A1/2 (T in rs2472297) and AHR (T in 
rs6968865; G in rs6968554; C in rs4410790)23. Information on genotyping and related quality control is provided in 
the supplementary text (Supplementary Table S1). In secondary analyses we used rs17685, rs9902453, rs1260326, 
rs1481012, rs7800944, and rs6265 for POR, EFCAB5, GCKR, ABCG2, MLXIPL, and BDNF, respectively.
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Habitual coffee, tea and caffeine consumption. Coffee intake was the primary exposure of interest, 
with tea and caffeine consumption only used in the secondary analyses. Habitual coffee consumption (cups/
day) in each cohort was computed using the available self-reported intake information, and in cohorts where 
the intake was indicated in an interval (e.g. 2 to 4 cups a day), the median was used. A categorical indicator for 
the intake level (<1, 1–4 and ≥4 cups/day) was also created for the purpose of stratification in subgroup analy-
ses. Habitual tea consumption (cups/day) was computed the same way as the habitual coffee consumption, and 
habitual caffeine intake (mg/day) was approximated by combining information on coffee and tea consumption 
and assuming that one cup of coffee and tea contained approximately 75 mg and 40 mg of caffeine, respectively23. 
Information on other caffeinated drinks (e.g. energy drinks, hot chocolate) was not available for most of the stud-
ies, and hence was not included in the computation for habitual caffeine intake. Detailed descriptions for coffee 
and tea intake information in each cohort can be found in the supplementary text (Supplementary Table S2).
Global cognition and memory scores. Cognitive measures included in the cohorts ranged from tests of 
global cognition such as the Mini-Mental State Examination (MMSE) to domain specific tests such as the Trail 
Making Tests, Digit Symbol Coding and the Paired Associates Learning test (Supplementary Table S3). Given the 
diversity of cognitive measures across cohorts, we computed composite global cognition and memory scores and 
used them as our primary outcomes. Those composite scores were constructed within each cohort by summing 
the standardized scores of the relevant cognitive tests. Such composite scores are regularly used as a way of pro-
ducing a more stable representation of cognitive function, harmonizing outcomes between cohorts, and maxi-
mizing interpretability26. Individual cognitive tests used in the global cognitive and memory scores were all coded 
to have higher scores as indicative of better cognitive function. Aside from the composite cognitive scores in the 
primary analyses, domain-specific cognitive measures in the UK Biobank, including reaction time (N = 288,905), 
pairs matching (N = 290,574), reasoning (N = 93,512) and prospective memory (N = 95,340) were used in the 
secondary analyses for domain-specific effects.
Statistical analyses. Three primary association analyses were performed, including (1) the phenotypic 
associations between the habitual coffee intake patterns and global cognition and memory function, (2) genetic 
associations between the genetic score indexing higher coffee intakes and global and memory cognition, and 
(3) instrument validation assessing the association between the genetic instruments and coffee intake patterns. 
For the genetic associations, since the coffee-cognition relationship may vary by intake level, we performed the 
association analyses under different levels of habitual coffee intake (1–4 and ≥4 cups/day). As a negative control, 
we also examined the genetic associations among non-coffee drinkers (<1 cup/day). For all three association 
analyses we used the linear regression and fitted two models, with model 1 including sex and age as covariates, 
and model 2 adjusted for sex, age, smoking (non-current and current smokers), education attainment and depres-
sion. In the genetic analyses we assumed an additive inheritance model, and additionally adjusted for principal 
components (PCs) to account for population stratification.
We performed secondary subgroup analyses to test if the genetic and phenotypic associations varied by age 
(<65 or ≥65 years) or sex. Since the genetic instruments indexing habitual coffee intake likely influence the 
intake patterns through affecting caffeine clearance23–25, we conducted secondary analyses for habitual tea and 
caffeine intakes (similar to the analyses performed for habitual coffee intake), with analyses on tea consumption 
further restricting the data to participants who did not drink coffee. Further, in the UK Biobank with a sample 
size up to 290,574, we performed domain-specific analyses to complement our primary findings using compos-
ite cognitive scores. Additional sensitivity analyses were conducted using alternative genetic instruments (POR 
and EFCAB5) to index habitual coffee intakes. Furthermore, we conducted analyses using an alternative MR 
approach, MR-Egger regression, which is suggested to be robust to pleiotropy27 and which therefore allowed us to 
use all eight genome-wide significant variants associated with habitual coffee intake patterns (CYP1A1/2, AHR, 
POR, EFCAB5, GCKR, ABCG2, MLXIPL, and BDNF)21.
Data analyses were conducted in each participating cohort, and the results were sent to the University of 
South Australia for quality control and meta-analyses. To ensure the uniformity in data analysis across cohorts, a 
detailed analysis plan and related statistical script was supplied to all cohorts. Random-effects models were used 
for the meta-analyses, with sensitivity analyses using fixed effects in the absence of heterogeneity. Meta-regression 
was used to assess variation by cohort characteristics, including age, sex or country. Further, power analyses28 
were performed to determine the minimal effect size we were powered to detect in the primary and domain 
specific genetic association analyses. All data analyses were performed using Stata (StataCorp LP, College Station, 
Texas, USA).
Results
Information for coffee intake was available for 415,530 participants from 10 European cohorts, including 300,760 
coffee consumers. Basic characteristics for participants in different studies are shown in Table 1. Median daily 
coffee consumption ranged from 2 to 4 cups/day (Table 1), with more coffee being consumed daily in Finland 
and Sweden than in the UK. Allele frequencies for AHR and CYP1A1/2 were consistent with those reported 
for the respective populations in the 1000 Genomes project. The genotype frequencies of both variants were in 
Hardy-Weinberg equilibrium in all cohorts (P > 0.07).
Phenotypic associations. There was no evidence for an overall phenotypic association between habitual 
coffee intake and global cognition or memory function (Table 2). Although higher coffee intake appeared to be 
associated with lower global cognitive scores in the sex and age adjusted analyses (Table 2, P = 0.04), this tentative 
association was no longer present after further adjustment for smoking, education level and depression (Table 2, 
P = 0.26).
www.nature.com/scientificreports/
4SCIENTIFIC RepoRts |  (2018) 8:7526  | DOI:10.1038/s41598-018-25919-2
There was considerable variability in the phenotypic associations across studies, with I2 ranging from 66% to 
85% (Pheterogeneity ≤ 0.003 for all comparisons, Table 2). However, there were no systematic study level differences 
in the phenotypic associations by age, sex or country (Pmeta-regression > 0.05 for all).
Genetic associations and instrument validation. Genetic associations were not affected by adjustment 
for smoking, education level and depression. Results are presented for the simpler model with adjustment for sex, 
age, and PCs to minimize the risk of collider bias potentially introduced by the statistical adjustment29.
CYP1A1/2, AHR and the genetic score showed the expected patterns with habitual coffee consumption 
(Fig. 1), with each allele on the genetic score associated with an average of 0.16 additional cups of coffee/day (95% 
C.I. 0.12–0.20, P = 3 × 10−15).
There was no evidence for an association between the genetic score with global cognition or memory among 
habitual coffee drinkers (P > 0.5 for both, Fig. 2), with high consistency between the cohorts (I2 ≤ 4% for both, 
Table 2 and Supplementary Fig. S6). Further, there was also no evidence for variation in the genetic effect by the 
degree of habitual coffee intake (Fig. 2, Pheterogeneity ≥ 0.56 for both global cognition and memory). As expected, 
in analyses restricted to participants who did not drink coffee as the negative control, the genetic score was not 
associated with global cognition or memory (P > 0.09 for both, Fig. 2).
Secondary analyses. Phenotypic and genetic effects did not vary by age (<65 yrs or ≥65 yrs) or sex 
(Pheterogeneity > 0.19 for all comparisons). Sensitivity analyses using two additional variants associated with coffee 
consumption, POR and EFCAB521, provided no consistent evidence for association with global or memory cog-
nition (Supplementary Fig. S2). An isolated association with memory function was seen for EFCAB5 (P = 0.004), 
a variant which had previously been suggested to be “non-pleiotropic” indicator for coffee consumption12, but 
which is located near the serotonin transporter21. MR-Egger regression, using all eight genome-wide signifi-
cant variants associated with habitual coffee intake21, also provided no evidence for association with global or 
memory cognition (−0.0096 [95% C.I. −0.056 to 0.036], and 0.0054 [95% C.I. −0.048 to 0.058], respectively). 
Domain specific information was available in the UK Biobank for reaction time (N = 288,905), pairs matching 
(N = 290,574), reasoning (N = 93,512) and prospective memory (N = 95,340). The genetic score was not associ-
ated with reaction time, pairs matching, or reasoning among coffee drinkers (P ≥ 0.05 for all, Fig. 3). For prospec-
tive memory the results were inconclusive (P = 0.047), however, this nominal benefit was not consistently seen in 
across caffeine intake variants (Supplementary Fig. S3).
Intake-increase alleles of CYP1A1/2, AHR and the genetic scores associated with increased habitual tea and 
caffeine intake in a dose-dependent matter (Supplementary Fig. S4). We examined the association of the genetic 
score with cognition among tea/caffeine consumers, including corresponding subgroup analyses, with null asso-
ciations found in all these analyses (Supplementary Fig. S5). Sensitivity analyses on tea consumption restricting 
Country N* Males (%)
Age, yrs Coffee intake, cups/day Global scores 
Median 
(IQR)
Memory 
scores Median 
(IQR)
AHR 
MAF (%)
CYP1A1/2 
MAF (%)≥65 yrs (%)
Median 
(IQR)
1–4 cups/
day (%)
≥4 cups/
day (%)
Median 
(IQR)
1958BC UK 4,416 50.7 0.0 50 (0) 48.1 18.6 3 (1) 0 (1.3) 0.04 (1.3) 38.7 26.4
ALSPAC-M UK 4,734 0.0 0.0 51 (6) 53.1 21.3 2 (3) 0.03 (1.4) 0.13 (1.3) 36.2 26.5
UK Biobank UK 404,620 46.0 19.6 58 (12) 51.4 20.4 2 (3) 0.2 (1.1) 0.34 (1.2) 36.4 26.7
HBCS Finland 1,653 41.5 90.0 68 (4) 73.2 17.0 2.5 (0.4) 0.08 (1.3) 0.12 (1.3) 35.6 19.6
NFBC1966 Finland 3,488 43.5 0.0 47 (1) 32.2 63.4 4 (3) −0.06 (1.2) −0.06 (1.2) 31.6 24.6
YFS Finland 2,323 45.7 0.0 43 (9) 38.2 44.1 4 (3) 0.14 (1.3) 0.22 (0.9) 31.4 25.0
PIVUS Sweden 882 49.9 100.0 70 (0) 62.4 30.1 3.1 (1.9) 0.18 (1) 0.17 (1.2) 35.9 28.7
ULSAM Sweden 1,081 100.0 100.0 71 (1) 63.2 32.4 3.4 (1.9) −0.16 (1.2) — 34.7 26.8
STR Sweden 1,073 45.0 76.1 72 (10) 45.3 51.1 4 (2) 0.05 (1.4) −0.09 (1.5) 37.7 28.7
TwinGene Sweden 2,370 51.3 100.0 69 (6) 53.9 40.1 3 (2) 0.09 (1.2) 0.16 (1.2) 34.8 27.7
Table 1. Characteristics of the participating cohorts. IQR: interquartile range; MAF: minor allele frequency. 
*Numbers reflect the maximal sample of individuals from each cohort who had genetic data.
Global cognition Memory cognition
N β* (95% C.I.) P I2 Pheterogeneity N β* (95% C.I.) P I2 Pheterogeneity
Phenotypic effect (cups/day) 300,806 −0.02(−0.039, −0.001) 0.04 85 <0.001 301,850
−0.012
(−0.029, 0.005) 0.16 80 <0.001
Adjusted phenotypic effect (cups/day) 295,823 −0.008(−0.023, 0.006) 0.26 74 <0.001 296,777
−0.004
(−0.017, 0.01) 0.58 66 0.003
Genetic effect (intake-increase-allele)# 300,760 −0.0007(−0.009, 0.008) 0.87 4 0.40 301,804
−0.001
(−0.005, 0.002) 0.51 0 0.64
Table 2. Phenotypic and genetic associations of habitual coffee intake with cognition. *All models adjusted for 
sex and age, with the adjusted phenotypic model controlling further on smoking, education and depression and 
the genetic models additionally adjusting for principal components. #Among coffee drinkers.
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data to participants who did not drink coffee (N = 103,064) also obtained null associations (P = 0.35 and 0.57 for 
global cognition and memory function, respectively). Detailed results can be found in the supplementary text.
Instrument validation in the UK Biobank. In the UK Biobank, the genetic score explained 0.33% of var-
iation in coffee consumption patterns (F-statistic = 952.6). There were no significant imbalances in allele distri-
bution of CYP1A1/2, AHR or genetic score by background covariates (P ≥ 0.05 for all, Supplementary Table S5).
Power calculations. For the genetic association, with a sample size of 300,760 (the sample size for global 
cognitive function) and a two-sided α level of 0.05, at 80% of power we would sufficiently detect a 0.0055 stand-
ard deviation (SD) change in the cognitive score for every coffee-intake-increase allele. Approximating from the 
distribution of coffee intake in the UK Biobank (SD = 2 cups/day), this translates into a causal effect of 0.045 SD 
by each cup of coffee. For the domain specific analyses in the UK Biobank, with the lowest sample size of 93,512 
(the sample size for the reasoning test), the effect size that we would be sufficiently powered to detect is 0.0099 SD 
for a continuous outcome and 0.024 log odds ratio (log OR, OR 1.02) for a binary outcome. This translates into a 
0.081 SD and 0.20 log OR (OR 1.22) by each cup of coffee, respectively.
Discussion
Our large-scale genetic analyses including over 300,000 coffee drinkers did not find any evidence to support 
beneficial or adverse long-term effects of coffee intake on global cognition or memory. Our findings are in line 
with a recent Mendelian randomization study on Alzheimer’s disease12, but contrasts with earlier observational 
studies14, alleviating concerns about potentially adverse effects on memory function. Our null finding is con-
vincing given the power to detect even very small effects, and as the results were remarkably consistent between 
cohorts, and also across different genetic variants used to index habitual coffee intake. While our analyses did 
not provide evidence for long-term benefits, these data suggest that there are no adverse effects on memory or 
cognitive function.
Mendelian randomization has become an increasingly popular approach for examining causal relationships, 
and it has begun to show its potential by clarifying a number of previously misconceived associations30,31. For 
studies to investigate the effects of coffee intake, it has the obvious attraction in the ability to test the preventative 
potential before advancing to more costly intervention studies. However, as used in the present study, Mendelian 
randomization has great prospects in addressing safety concerns with exposures considered to be potentially 
harmful.
Global cognitive function encompasses several domains with each domain itself being a complex entity32. It is 
possible that the effect of habitual coffee consumption may vary from one domain to another. If this is true, then 
composite cognitive scores capturing different cognitive domains may potentially dilute any domain-specific 
effects. Domain-specific analyses were conducted using smaller sub-samples of the UK Biobank with available 
information, with no evidence for either benefit or harm by coffee intake. Some uncertainty remains with pro-
spective memory, where results were borderline, retaining the possibility of some nominal benefit. Given that 
this effect was not consistently observed across all instruments for habitual coffee intake it is most likely to be a 
chance finding.
In Mendelian randomization the ability to make causal inferences directly depends on the availability and 
quality of genetic instruments. Genome-wide association studies to date have identified eight loci influencing 
habitual coffee intakes21,22, including CYP1A1/2, AHR, POR, EFCAB5, GCKR, ABCG2, MLXIPL, and BDNF. 
We chose to use the two strongest variants to construct our primary instrument, as both consistently associate 
with habitual coffee intake21–23 and have well-characterized biological mechanisms influencing caffeine metab-
olism which plausibly explain their association with coffee intake24. However, pleiotropic effects cannot be fully 
Figure 1. Association of AHR, CYP1A1/2 and genetic score with habitual coffee intake (cups/day) among coffee 
drinkers. Error bars are the 95% confidence intervals.
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Figure 2. Association of genetic score with global (a) and memory (b) cognition among coffee drinkers and in 
subgroups stratified by coffee intake (<1, 1–4 or ≥4 cups/day), sex and age (<65 yrs or ≥65 yrs). *Among coffee 
consumers; −, + and ++ denote <1, 1–4 and ≥4 cups/day, respectively. Error bars are the 95% confidence 
intervals.
Figure 3. Association of the genetic score with different cognitive tests among coffee consumers in the UK 
Biobank. For all cognitive tests, positive effect sizes indicate improvements in cognitive function. For the 
prospective memory (i.e. a binary outcome), odds = probability of being correct/probability of being incorrect 
at the first attempt. Error bars are the 95% confidence intervals. #Effect size is change in cognitive scores per 
intake-increase allele; $Effect size is change in log odds ratio per intake-increase allele.
www.nature.com/scientificreports/
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excluded given genome-wide association analyses on Parkinson’s disease, blood pressure and bladder cancer have 
shown signals both for AHR and CYP1A1/233–35, although these weak associations could reflect downstream 
causal effects of caffeine or coffee consumption36. To exclude the possibility that the null association with cogni-
tive function which we observed in this study is driven by opposing patterns induced by pleiotropy in AHR and/
or CYP1A1/2, we conducted sensitivity analyses in the UK Biobank using other variants to index habitual coffee 
consumption21 and replicated our main analyses including POR and EFCAB5, which have unknown effects on 
caffeine metabolism but which did not have previously reported pleiotropic effects. Also these analyses provided 
no support for causal effects of habitual coffee intake on cognition, although there appeared to be an association 
between memory function and rs9902453, located in the intron of the EFCAB5. There is very limited information 
on EFCAB5 in the literature, however, the variant is in close proximity to SLC6A4, the gene encoding serotonin 
transporter21. Serotonin affects cognitive abilities, in particular memory consolidation37, hence, the observed 
rs9902453–memory function association is likely a reflection of a pleiotropic effect than a true causal effect of cof-
fee intake. Pleiotropy was also considered to be a problem with four other variants identified in the earlier GWAS 
on coffee consumption (notably GCKR, ABCG2, MLXIPL, and BDNF)21, which according to the GWAS catalogue, 
had shown primary associations with traits including BMI, smoking initiation, and gout12. In further sensitivity 
analyses we included all eight coffee intake associated variants21 in the MR-Egger regression which is robust to 
pleiotropy27. However, any change in our instrument selection strategy did not affect our conclusions, and also 
these analyses provided no support for any causal association between habitual coffee intake and cognition.
As secondary analyses, we examined the association of the genetic instruments with habitual tea and caffeine 
intakes. While people who consume more coffee tend to drink less tea, our analyses suggest that the genetic driv-
ers for coffee and tea consumption are similar. This, together with the known functions of CYP1A1/2 and AHR, 
confirm that influences on caffeine metabolism likely explains the association between the genetic instruments 
and habitual coffee intake. It can be argued as a limitation with our approach that the genetic instruments, which 
were used to index habitual coffee intake, can also index habitual tea intake. However, it is unlikely that a causal 
coffee-cognition relationship would have been confounded by habitual tea intakes in our study, given the notably 
weaker genetic influences on tea than on coffee consumption. Further, it needs to be noted that, any inferences 
relating to caffeine will need to be drawn with caution as the instruments indexing greater caffeine consumption 
may reflect a faster rate of caffeine clearance, and hence a lower (rather than higher) circulating levels of bioactive 
caffeine38.
As a further limitation, it can be argued that our genetic association results among coffee drinkers could have 
been affected by the collider bias as the genetic score indexing the extent of habitual coffee intake is also associated 
with the probability of being a coffee drinker39. However, sensitivity analyses in the UK Biobank study conducted 
in the coffee and non-coffee drinkers combined, also showed a null association (results not shown). Also, while 
the test for the association between the genetic score and the outcome is a valid test for a causal relationship40, it 
cannot estimate the magnitude of the causal effect if it exists. However, given that null associations were observed 
in our study, there would have been little gain in applying additional methods (such as instrumental variable 
analyses)41 to quantify these ‘null’ effects.
In conclusion, we found no evidence that habitual coffee consumption is causally associated with global and 
memory cognition in mid- to later-life, despite the power to detect very small effects. This suggests that inter-
ventions to protect cognition or slow cognitive decline using coffee are unlikely to be successful and should not 
be prioritized in future trials. That said, there was no evidence for any adverse effect, contrary to some previous 
observational studies, and hence it appears safe to consume coffee at least with respect to preserving memory 
function.
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